Apimeds Pharmaceuticals US Net Income
| APUS Stock | 1.78 0.07 3.78% |
As of the 2nd of February, Apimeds Pharmaceuticals shows the Mean Deviation of 7.01, insignificant risk adjusted performance, and Standard Deviation of 10.21. Apimeds Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apimeds Pharmaceuticals coefficient of variation and value at risk to decide if Apimeds Pharmaceuticals is priced correctly, providing market reflects its regular price of 1.78 per share. Please also double-check Apimeds Pharmaceuticals US jensen alpha, which is currently at (0.29) to validate the company can sustain itself at a future point.
Apimeds Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Apimeds Pharmaceuticals' valuation are provided below:Apimeds Pharmaceuticals US does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Stock market expansion? Will Apimeds introduce new products? Factors like these will boost the valuation of Apimeds Pharmaceuticals. If investors know Apimeds will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apimeds Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Apimeds Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Apimeds's balance sheet. Smart investors calculate Apimeds Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Apimeds Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Apimeds Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apimeds Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Apimeds Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Apimeds Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apimeds Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apimeds Pharmaceuticals.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Apimeds Pharmaceuticals on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Apimeds Pharmaceuticals US or generate 0.0% return on investment in Apimeds Pharmaceuticals over 90 days. Apimeds Pharmaceuticals is related to or competes with Talphera, MIRA Pharmaceuticals, Scynexis, Milestone Scientific, India Globalization, Precision Optics, and Q32 Bio. More
Apimeds Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apimeds Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apimeds Pharmaceuticals US upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 59.03 | |||
| Value At Risk | (20.79) | |||
| Potential Upside | 15.05 |
Apimeds Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apimeds Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apimeds Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Apimeds Pharmaceuticals historical prices to predict the future Apimeds Pharmaceuticals' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.10) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Apimeds Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Apimeds Pharmaceuticals February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 7.01 | |||
| Coefficient Of Variation | (5,376) | |||
| Standard Deviation | 10.21 | |||
| Variance | 104.27 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.10) | |||
| Maximum Drawdown | 59.03 | |||
| Value At Risk | (20.79) | |||
| Potential Upside | 15.05 | |||
| Skewness | 0.2785 | |||
| Kurtosis | 1.73 |
Apimeds Pharmaceuticals Backtested Returns
Apimeds Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0186, which signifies that the company had a -0.0186 % return per unit of risk over the last 3 months. Apimeds Pharmaceuticals US exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Apimeds Pharmaceuticals' Mean Deviation of 7.01, standard deviation of 10.21, and insignificant Risk Adjusted Performance to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Apimeds Pharmaceuticals will likely underperform. At this point, Apimeds Pharmaceuticals has a negative expected return of -0.19%. Please make sure to confirm Apimeds Pharmaceuticals' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Apimeds Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.22 |
Weak reverse predictability
Apimeds Pharmaceuticals US has weak reverse predictability. Overlapping area represents the amount of predictability between Apimeds Pharmaceuticals time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apimeds Pharmaceuticals price movement. The serial correlation of -0.22 indicates that over 22.0% of current Apimeds Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.22 | |
| Spearman Rank Test | -0.45 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Apimeds Pharmaceuticals US reported net income of (1.39 Million). This is 100.41% lower than that of the Capital Markets sector and 99.64% lower than that of the Financials industry. The net income for all United States stocks is 100.24% higher than that of the company.
Apimeds Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apimeds Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apimeds Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apimeds Pharmaceuticals by comparing valuation metrics of similar companies.Apimeds Pharmaceuticals is currently under evaluation in net income category among its peers.
Apimeds Fundamentals
| Return On Asset | -4.09 | |||
| Current Valuation | 21.11 M | |||
| Shares Outstanding | 11.58 M | |||
| Shares Owned By Insiders | 81.96 % | |||
| Number Of Shares Shorted | 3.22 K | |||
| EBITDA | (1.27 M) | |||
| Net Income | (1.39 M) | |||
| Total Debt | 596.84 K | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (733.53 K) | |||
| Short Ratio | 0.01 X | |||
| Earnings Per Share | (0.13) X | |||
| Market Capitalization | 24.31 M | |||
| Total Asset | 13.06 K | |||
| Retained Earnings | (4.39 M) | |||
| Working Capital | (1.01 M) | |||
| Net Asset | 13.06 K |
About Apimeds Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apimeds Pharmaceuticals US's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apimeds Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apimeds Pharmaceuticals US based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.